Dr. David Eifrig's *Prosperity Investor*

No detailed brain note yet for Dr. David Eifrig's *Prosperity Investor*. USPs will populate as FID mines its promos.

• Eifrig Retirement Shock

  Backend VSLOld (Inactive)7.8/10
  2026-06-25· Dr. David Eifrig's *Prosperity Investor*· Teases: The promo contains three distinct stock teases in the "Step Two" section: **Tease #1 — At-Home Cancer Test Company:** - Clues: Creates a simple, at-home test for a cancer that "affects more people than all other cancers combined" (colorectal cancer is the most common by this metric); technology is cheaper and non-invasive vs. existing detection methods; already FDA-approved; covered by Medicare; covered by largest insurers in largest states; stock is "so cheap today that it could rise 15-fold just to get back to where it was before the recent market freak-out"; small/mid-cap (implied by the 15x recovery language) - Best prediction: **Exact Sciences (EXAS)** — maker of Cologuard, the at-home colorectal cancer screening test; FDA-approved, Medicare-covered, had crashed significantly from 2021 highs by mid-2022 - Confidence: **High** **Tease #2 — AI Diagnostic Handheld Device:** - Clues: Handheld device that plugs into a doctor's smartphone; replaces machines costing 10x as much; makes screening available at point-of-care and in the field; founder won a presidential award for contributions to genome mapping; backed by Bill Gates; revenue up 35% last year; founder has three prior successful companies - Best prediction: **Butterfly Network (BFLY)** — makes a handheld ultrasound device that plugs into a smartphone; founder Jonathan Rothberg won a presidential award for genome sequencing contributions; backed by Gates; fits the "10x cheaper" and field-deployable profile - Confidence: **Medium-High** **Tease #3 — Pure Biotech with $4B Bristol Myers Partnership:** - Clues: Pure biotech play; technology was featured at the American Society of Clinical Oncology (ASCO) meeting; signed a $4+ billion partnership with Bristol Myers Squibb; potential for 500%-1,000%+ gains - Best prediction: **Turning Point Therapeutics (TPTX)** — precision oncology company that was acquired by Bristol Myers Squibb for $4.1 billion (122% premium, mentioned earlier in the letter); however, since the letter mentions this buyout as already completed, the tease may refer to a different company. Alternative: **Mirati Therapeutics (MRTX)** or **Karuna Therapeutics** — both had significant ASCO presence and BMS partnership discussions in 2022 - Confidence: **Low-Medium** (the BMS/ASCO clues are strong but the already-completed Turning Point acquisition creates ambiguity about whether this is a different company)

  1. Hook Strength: 7/10 — The eyebrow (MD, MBA, "Major Warning") combined with the "life or death" dual-stakes framing creates genuine stopping power, but the opening pages spend too long on Eifrig's personal feelings before delivering the core idea, risking early drop-off from impatient skeptics. 2.

No emails captured yet (iSpy not connected).